GGrantIndex
← Leaderboards

Laurel L Lenz

University Of California Berkeley

$13,007,441
Attributed
$14,062,402
Total exposure
13
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200625
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$14,062,402 · 13

By mechanism

R01$8,397,638 · 4
T32$2,109,923 · 1
R21$1,709,555 · 4
R33$1,129,947 · 1
R56$396,250 · 1
U54$200,285 · 1

Top collaborators

Most similar at University Of California Berkeley

Same institution · by research overlap

Others in their field

Top investigators on “Infection

Research focus

InfectionResponseProteinsListeria MonocytogenesBacterial InfectionsCellsPathogenProductionPathogenic BacteriaPredispositionBacteriaPreventHost ResistanceInterferonsMacrophageImmunityCytokineInflammatoryReceptorSystemic InfectionImmune ResponseVirulenceImmuneInterferon Type Ii

Grant awards (43)

Dendritic cell targeting by bacterial LysM proteins to suppress inflammation$463,755
R01 · FY2025 · AI · contact PI
Training Program in Immunology$460,692
T32 · FY2025 · AI
Training Program in Immunology$532,574
T32 · FY2024 · AI
Dendritic cell targeting by bacterial LysM proteins to suppress inflammation$463,755
R01 · FY2024 · AI · contact PI
Training Program in Immunology$566,625
T32 · FY2023 · AI
Dendritic cell targeting by bacterial LysM proteins to suppress inflammation$463,755
R01 · FY2023 · AI · contact PI
Training Program in Immunology$550,032
T32 · FY2022 · AI
Role of IFNs and IFNGR in susceptibility to bacteria in Down syndrome$190,965
R21 · FY2022 · AI · contact PI
NK cell IL-10 production during bacterial infections$565,046
R01 · FY2021 · AI · contact PI
Role of IFNs and IFNGR in susceptibility to bacteria in Down syndrome$230,121
R21 · FY2021 · AI · contact PI
NK cell IL-10 production during bacterial infections$716,956
R01 · FY2020 · AI · contact PI
NK cell IL-10 production during bacterial infections$61,841
R01 · FY2020 · AI · contact PI
NK cell IL-10 production during bacterial infections$480,003
R01 · FY2019 · AI · contact PI
Myeloid cell IFNGR regulation in persistent viral and secondary bacterial infections$190,645
R21 · FY2019 · AI · contact PI
NK cell IL-10 production during bacterial infections$92,090
R01 · FY2019 · AI · contact PI
NK cell IL-10 production during bacterial infections$480,003
R01 · FY2018 · AI · contact PI
Myeloid cell IFNGR regulation in persistent viral and secondary bacterial infections$229,828
R21 · FY2018 · AI · contact PI
NK cell IL-10 production during bacterial infections$480,003
R01 · FY2017 · AI · contact PI
Active Subversion of Innate Immunity by Bacterial LysM Protein$409,029
R01 · FY2016 · AI · contact PI
IFNGR Down Regulation as a Host Target for Therapy of Infectious Diseases$362,376
R33 · FY2016 · AI · contact PI
Active Subversion of Innate Immunity by Bacterial LysM Protein$450,656
R01 · FY2015 · AI · contact PI
IFNGR Down Regulation as a Host Target for Therapy of Infectious Diseases$367,624
R33 · FY2015 · AI · contact PI
Active Subversion of Innate Immunity by Bacterial LysM Protein$460,125
R01 · FY2014 · AI · contact PI
IFNGR Down Regulation as a Host Target for Therapy of Infectious Diseases$399,947
R33 · FY2014 · AI · contact PI
Non-canonical responses to IFNab in the suppression of macrophage immunity$166,245
R21 · FY2014 · AI · contact PI
Non-canonical responses to IFNab in the suppression of macrophage immunity$28,126
R21 · FY2014 · AI · contact PI
Active Subversion of Innate Immunity by Bacterial LysM Protein$372,475
R01 · FY2013 · AI · contact PI
Non-canonical responses to IFNab in the suppression of macrophage immunity$237,750
R21 · FY2013 · AI · contact PI
IFNGR Down Regulation as a Host Target for Therapy of Infectious Diseases$198,125
R21 · FY2013 · AI · contact PI
Active Subversion of Innate Immunity by Bacterial LysM Protein$45,179
R01 · FY2013 · AI · contact PI
IFNGR Down Regulation as a Host Target for Therapy of Infectious Diseases$237,750
R21 · FY2012 · AI · contact PI
Active Subversion of Innate Immunity by Bacterial LysM Protein$196,225
R01 · FY2012 · AI · contact PI
Active Subversion of Innate Immunity by Bacterial LysM Protein$396,250
R56 · FY2011 · AI · contact PI
Immune Modulation by Bacterial Autolysins$367,781
R01 · FY2010 · AI · contact PI
Immune Modulation by Bacterial Autolysins$371,495
R01 · FY2009 · AI · contact PI
CD8 Mediated Apoptosis During T Cell Development$317,281
R01 · FY2009 · AI · contact PI
Secondary Characterizations of Candidate F. tularensis NFkB Inhibitors$200,285
U54 · FY2009 · AI · contact PI
Immune Modulation by Bacterial Autolysins$371,495
R01 · FY2008 · AI · contact PI
Immune Modulation by Bacterial Autolysins$378,690
R01 · FY2007 · AI · contact PI
Immune Modulation by Bacterial Autolysins$390,000
R01 · FY2006 · AI · contact PI
PHASE VARIATION IN LISTERIA MONOCYTOGENES$46,192
F32 · FY2002 · AI
PHASE VARIATION IN LISTERIA MONOCYTOGENES$40,196
F32 · FY2001 · AI
PHASE VARIATION IN LISTERIA MONOCYTOGENES$32,416
F32 · FY2000 · AI